Faes Farma (FAE.MC)

Executive Summary

Faes Farma S.A. is a vertically integrated Spanish pharmaceutical company founded in 1933, with a global presence in over 130 countries. Specializing in small molecule pharmaceuticals for human health and animal nutrition, the company reported revenues of €627 million in 2025 and holds a market valuation of approximately $1.43 billion. Faes Farma combines chemical synthesis expertise with a diversified product portfolio, including established brands such as Bilastine for allergic conditions and Hemorrane for hemorrhoids. The company's vertical integration and commitment to R&D enable it to maintain a competitive edge in the generic and specialty pharmaceutical markets. Faes Farma's pipeline includes several completed trials, with a key ongoing focus on Mesalazine for ulcerative colitis (Phase 3, completed in August 2025, pending data analysis). The company also explores new formulations of Bilastine, including an ophthalmic solution for allergic conjunctivitis, which completed Phase 3 in 2018. While the near-term pipeline is limited, Faes Farma's strong commercial base and global distribution network provide a solid foundation for growth. Upcoming catalysts include the potential readout of Mesalazine Phase 3 data and possible regulatory filings for Bilastine ophthalmic in select markets.

Upcoming Catalysts (preview)

• Q3 2026Mesalazine Phase 3 Data Readout for Ulcerative Colitis70% success
• H2 2026Regulatory Submission for Bilastine Ophthalmic Solution60% success
• TBDNew Partnership or Licensing Deal for Bilastine in Emerging Markets50% success